Closure of persistent arterial duct in preterm newborns. use of IV diclofenac sodium - Hospital de San José Bogotá DC.
Cierre de Ductus Arterioso persistente en neonatos pretérmino uso de diclofenaco sódico endovenoso, hospital de San José, Bogotá DC
Article Sidebar
PDF (Español (España))
FLIP
Main Article Content
Abstract
Persistent arterial duct (PAD) increases the risk of intraventricular hemorrhage, necrotizing enteropathy, bronchial/ pulmonary dysplasia and death. lndomethacin is considered the preferred drug for pharmacological closure of PAD. Diclofenac sodium is used as an alternative due to import-related restrictions for indomethacin in our Objective: use of IV diclofenac for PAD closure in preterm newborns at Hospital de San de José, Bogotá, from February 2007 to June 2010. Design and Methodology: this is a descriptive retrospective study conducted in 38 preterm newborns O to 20 days after birth who have been diagnosed with PAD, hemodynamic repercussion, and/or major diameter greater than 2 mm, who received diclofenac for pharmacologic closure. Results: closure was achieved with only one cycle in 81.5%. 65.8% required less than seven days of ventilatory support. Major complications were renal and neurological, with few adverse reactions. Conclusions: diclofenac showed a good rate of PAD closure with few adverse effects, thus it can be considered an alternative to handle this condition when standard therapy is not available. Nonetheless, we consider new comparative studies are necessary in order to obtain relevant conclusions.
Keywords:
Downloads
Article Details
References
2. Evans N. Current controversies in tbe diagnosis and treatrnent of patent ductus arteriosus in preterm infants. 2003 Aug;(4):168-77.
3. Vanbaesebrouck S, Zonnenberg I, Vandervoort P, Bruneel E, Van Hoes tenberghe MR, T heyskens C. Conservative treatment for patent ductus arteriosus in the preterm. 2007 Ju1;(4):F244-F247.
4. Weir EK, López-Bameo J, Buckler KJ, Arcber SL. Acute oxygen-sensing mecbanisms. 2005 Nov 10;(19):2042-55.
5. Cooke L, Steer P, Woodgate P. Indomethacin for asymptomatic patent ductus arteriosus in preterm infants. 2003;(2):CD003745.
6. Golombek SG, Sola A, Baquero H, Borbonet D, Cabanas F, Fajardo C, et al. [First SIBEN clinical consensus: diagnostic and therapeutic approacb to patent ductus arteriosus in premature newborns]. 2008 Nov;(5):454-81.
7. van OB,-Smets K, Lecoutere D, Van de Broek H, Weyler J, Degroote K, et al. A comparison ofibuprofen and indomethacin for closure ofpatent ductus arteriosus. 2000 Sep 7;(10):674-81.
8. Eichenwald EC, Stark AR. Management and outcomes ofvery low birth weight. 2008 Apr 17;(16):1700-11.
9. Hamrick SE, Hansmann G. Patent ductus arteriosus ofthe preterm infant. 2010 May;(5):1020-30.
1O. Shah SS, Ohlsson A. Ibuprofen for the prevention ofpatent ductus arte riosus in preterm and/or low birtb weight infants. 2006;(1):CD004213.
11. Su BH, Lin HC, Cbiu HY, Hsieb HY, Cben HH, Tsai YC. Comparison of ibuprofen and indometacin for early-targeted treatment ofpatent ductus arteriosus in extremely premature infants: a randomised controlled tria!. 2008 Mar;(2):F94-F99.
12. GorkAS, Ehrenk.ranz RA, Bracken MB. Continuousinfusionversusinter mittent bolus doses ofindomethacin for patent ductus arteriosus closure in symptomati preterrn infant. 2008;(1):CD00607I.
13. Malviya M, Ohlsson A, Shah S. Surgical versus medica! treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants. 2008;(1):CD00395l.
14. Ohlsson A, Walia R, Shah S. Ibuprofen for the treatment ofpatent ductus arteriosus in preterrn and/orlow birth weight infants. 2008;(1):CD00348 l.
15. DiMenna L, Laabs C, McCoskey L, Seals A. Management ofthe neonate with patent ductus arteriosus. 2006 Oct;(4):333-40.
16. Schmidt B, Davis P, Moddemann D, Ohlsson A, Roberts RS, Saigal S, et al. Long-term effects ofindomethacin prophylaxis in extremely-low birth-weight infants. 2001 Jun 28;(26):1966-72.
17. Alano MA, Ngougmna E, Ostrea EM, Jr., Konduri GG. Analysis ofnons teroidal antiinflammatory drugs in meconium and its relation to persisten! pulmonary hypertension ofthe newbom. 2001 Mar;(3):5l 9-23.
18. Auer M, Brezinka C, Eller P, Luze K, Schweigmann U, Schwarzler P. P renatal diagnosis ofintrauterine premature closure ofthe ductus arteriosus following maternal diclofenac application. 2004 May;(5):513-6.
19. Luchese S, Manica JL, Zielinsky P. lntrauterine ductus arteriosus cons triction: analysis ofa historie cobort of20 cases. 2003 Oct;(4):405-4.
20. P aul AD, Chauhan CK. Study of usage pattem of nonsteroidal anti inflamrnatory drugs (NSAIDs) among different practice categories in Indian clinical setting. 2005 Feb;(l 2):889-92.
21. Siu KL, Lee WH. Maternal diclofenac sodium ingestion and severe neo natal pulmonary hypertension. 2004 Mar;(3):152-3.
22. Torloni MR, Cordioli E, Zamith MM, Hisaba WJ, Nardozza LM, Santana RM, et al. Reversible constriction ofthe fetal ductus arteriosus after ma ternal use oftopical diclofenac and methyl salicylate. 2006 Feb;(2):227-9.